Glucagon (swine) - CAS 16941-32-5
Catalog number: B0084-060732
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Glucagon, a peptide compound, is effective in increasing the glucose concentration in bloodstream and could be released by pancrea α cells.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-060732 10 mg $288 In stock
Bulk Inquiry
Glucagonum; Glucagone; HG-Factor; His-ser-glu(nh2)-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-ser-arg-arg-ala-glu(NH2)-asp-phe-val-glu(NH2)-trp-leu-met-asp(NH2)-thr; Glucagon-like-immunoreactivity; Glucaton
Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Quality Standard:
In-house standard
1.530 g/cm3
Canonical SMILES:
1.Glucagon responses to exercise-induced hypoglycaemia are improved by somatostatin receptor type 2 antagonism in a rat model of diabetes.
Leclair E1, Liggins RT2, Peckett AJ1, Teich T1, Coy DH3, Vranic M4, Riddell MC5. Diabetologia. 2016 Apr 13. [Epub ahead of print]
AIMS/HYPOTHESIS: Regular exercise is at the cornerstone of care in type 1 diabetes. However, relative hyperinsulinaemia and a blunted glucagon response to exercise promote hypoglycaemia. Recently, a selective antagonist of somatostatin receptor 2, PRL-2903, was shown to improve glucagon counterregulation to hypoglycaemia in resting streptozotocin-induced diabetic rats. The aim of this study was to test the efficacy of PRL-2903 in enhancing glucagon counterregulation during repeated hyperinsulinaemic exercise.
2.Glucoregulatory, endocrine and morphological effects of [P5K]hymenochirin-1B in mice with diet-induced glucose intolerance and insulin resistance.
Owolabi BO1, Ojo OO1,2, Srinivasan DK1, Conlon JM3, Flatt PR1, Abdel-Wahab YH1. Naunyn Schmiedebergs Arch Pharmacol. 2016 Apr 12. [Epub ahead of print]
The frog skin host-defence peptide hymenochirin-1B has been shown to stimulate insulin release in vitro from isolated pancreatic islets and BRIN-BD11 clonal β-cells. This study examines the effects of 28-day administration of a more potent analogue [P5K]hymenochirin-1B ([P5K]hym-1B) (75 nmol·kg-1 body weight) to high-fat-fed mice with obesity, glucose intolerance and insulin resistance. Treatment with [P5K]hym-1B significantly decreased plasma glucose concentrations and improved glucose tolerance, insulin secretion, insulin sensitivity and increased the magnitude of the incretin effect (difference in response to oral vs intraperitoneal glucose loads). Responses to established insulin secretagogues were greater in islets isolated from treated animals compared with saline-treated controls. [P5K]hym-1B administration significantly decreased total islet area and β- and α-cell areas, and resulted in lower concentrations of circulating triglycerides and plasma and pancreatic glucagon.
3.Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease.
Li L1, Liu K1, Zhao J1, Holscher C2, Li GL3, Liu YZ3. Neural Regen Res. 2016 Feb;11(2):326-31. doi: 10.4103/1673-5374.177742.
The growth factor glucagon-like peptide-1 (GLP-1) is neuroprotective in several animal models of neurodegeneration. Here, we analyzed the neuroprotective effects of a novel protease-resistant GLP-1 analogue, (Val(8))GLP-1-Glu-PAL, which has advantages over older analogues, such as improvement of hippocampal neurogenesis, glucose homeostasis, and insulin secretion. We established an in vitro model of Parkinson's disease using the mitochondrial stressor rotenone in primary cultured mouse neurons pretreated with (Val(8))GLP-1-Glu-PAL. (Val(8))GLP-1-Glu-PAL alone did not affect neuronal viability, but prevented the rotenone-induced reduction in cell viability in a dose-dependent manner. In addition, (Val(8))GLP-1-Glu-PAL pretreatment prevented rotenone-induced proapoptotic changes manifesting as downregulation of procaspase-3 and Bcl-2 and upregulation of cleaved caspase-3. These results demonstrate that the novel agent (Val(8))GLP-1-Glu-PAL shows promise as a drug treatment for Parkinson's disease.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 112665-43-7 Seratrodast

(CAS: 112665-43-7)

Seratrodast is a potent and selective thromboxane A2 receptor (TP) antagonist used primarily in the treatment of asthma.

(CAS: 1414375-50-0)

GSK-1268997 is one of a metabolite of Pazopanib which is a selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits an...

ML 352 hydrochloride

ML 352 hydrochloride is a selective presynaptic choline transporter inhibitor.

CAS 101917-30-0 Sodium 4-pentynoate

Sodium 4-pentynoate
(CAS: 101917-30-0)

Sodium 4-pentynoate, an alkynylacetate analogue, can be metabolically incorporated onto cellular proteins through biosynthetic mechanisms for profiling of acet...

(CAS: 1005334-57-5)

CVT10216 is a potent and selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2) with IC50 value of 29nM, thereby inhibiting dopamine synthesis. It ...

CAS 882268-69-1 HIF-2a Translation Inhibitor 76

HIF-2a Translation Inhibitor 76
(CAS: 882268-69-1)

A cell-permeable HIF-2a translation inhibitor (IC50 value 5 µM). It inhibits HIF-2a translation via enhancing the binding of IRP1 (Iron-Regulatory Protein 1) to...

CAS 115436-72-1 Risedronate Sodium

Risedronate Sodium
(CAS: 115436-72-1)

Risedronate Sodium is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.

CAS 1025015-40-0 GK921

(CAS: 1025015-40-0)

GK921 is a transglutaminase 2 (TGase 2) inhibitor with average GI50 of 0.9 μM in cancer cell lines.

Chemical Structure

CAS 16941-32-5 Glucagon (swine)

Quick Inquiry

Verification code

Featured Items